Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-CD19 chimeric antigen receptor T cells therapy - Shanghai Jibei biotechnology

Next Previous
Drug Profile

Anti-CD19 chimeric antigen receptor T cells therapy - Shanghai Jibei biotechnology

Alternative Names: Anti-CD19 CAR-T cells therapy - Shanghai Jibei biotechnology; CD19 CAR-T cells therapy - Shanghai Jibei biotechnology

Latest Information Update: 28 Nov 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Jibei biotechnology
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported B-cell lymphoma

Most Recent Events

  • 28 Nov 2022 No recent reports of development identified for clinical-Phase-Unknown development in B-cell lymphoma(Combination therapy, In adolescents, In the elderly, Second-line therapy or greater, In adults) in China (Infusion)
  • 13 Nov 2019 Safety and efficacy data from a clinical trial in B-cell lymphoma released by Shanghai Jibei biotechnology
  • 01 Sep 2018 Clinical trials in B-cell lymphoma (Combination therapy, Second-line therapy or greater, In adolescents, In adults, In the elderly) in China (Infusion) (ChiCTR1800018059)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top